Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway

References

• Bailly C. 2021. Anticancer properties of lobetyolin, an essential component of Radix Codonopsis (Dangshen). Nat Prod Bioprospect. 11(2):143–153.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Cao S, Li L, Li J, Zhao H. 2020. MiR-1299 impedes the progression of non-small-cell lung cancer through EGFR/PI3K/Akt signaling pathway. Onco Targets Ther. 13:7493–7502.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, El-Deiry WS. 2020. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 17(7):395–417.
   PubMed Web of Science ®Google Scholar
• Chen Q, Pan Z, Zhao M, Wang Q, Qiao C, Miao L, Ding X. 2018. High cholesterol in lipid rafts reduces the sensitivity to EGFR-TKI therapy in non-small cell lung cancer. J Cell Physiol. 233(9):6722–6732.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tian Y, Jin G, Cui Z, Guo W, Zhang X, Liu X. 2021. Lobetyolin inhibits the proliferation of breast cancer cells via ASCT2 down-regulation-induced apoptosis. Hum Exp Toxicol. https://doi.org/10.1177/09603271211021476.
   Web of Science ®Google Scholar
• Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58(3):621–681.
   PubMed Web of Science ®Google Scholar
• Chou TC. 2010. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70(2):440–446.
   PubMed Web of Science ®Google Scholar
• Cui QL, Ye P, Shu QJ, Shao M. 2015. Study on inhibitory effect of aqueous extract of Taxus Chinensis var. mairei combined erlotnib on A549 xenograft in nude mice and its mechanism. Zhongguo Zhong Xi Yi Jie He Za Zhi. 35:572–577.
   PubMedGoogle Scholar
• Ge HB, Zhu J. 2020. Clinical efficacy of Baihe Gujin decoction combined with anti-tuberculosis therapy for pulmonary tuberculosis with yin-deficiency and fire-hyperactivity syndrome. J Int Med Res. 48(5):300060519875535.
   PubMed Web of Science ®Google Scholar
• Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, et al. 2007. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin Cancer Res. 13(12):3713–3723.
   PubMed Web of Science ®Google Scholar
• Guo X, Ding X. 2018. Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/Akt/MAPK signaling pathways. Oncol Lett. 15(6):9537–9542.
   PubMed Web of Science ®Google Scholar
• Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, et al. 2016. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 22(3):262–269.
   PubMed Web of Science ®Google Scholar
• Heigener DF, Reck M. 2018. Lung cancer in 2017: giant steps and stumbling blocks. Nat Rev Clin Oncol. 15(2):71–72.
   PubMed Web of Science ®Google Scholar
• Hu E, Wang D, Chen J, Tao X. 2015. Novel cyclotides from Hedyotis diffusa induce apoptosis and inhibit proliferation and migration of prostate cancer cells. Int J Clin Exp Med. 8(3):4059–4065.
   PubMed Web of Science ®Google Scholar
• Iida M, Harari PM, Wheeler DL, Toulany M. 2020. Targeting AKT/PKB to improve treatment outcomes for solid tumors. Mutat Res. 819–820:111690.
   PubMed Web of Science ®Google Scholar
• Jiao L, Xu J, Sun J, Chen Z, Gong Y, Bi L, Lu Y, Yao J, Zhu W, Hou A, et al. 2019. Chinese herbal medicine combined with EGFR-TKI in EGFR mutation-positive advanced pulmonary adenocarcinoma (CATLA): a multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 10:732.
   PubMed Web of Science ®Google Scholar
• Kuo YT, Liao HH, Chiang JH, Wu MY, Chen BC, Chang CM, Yeh MH, Chang TT, Sun MF, Yeh CC, et al. 2018. Complementary Chinese herbal medicine therapy improves survival of patients with pancreatic cancer in Taiwan: a nationwide population-based cohort study. Integr Cancer Ther. 17(2):411–422.
   PubMed Web of Science ®Google Scholar
• Larsen AK, Ouaret D, El Ouadrani K, Petitprez A. 2011. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 131(1):80–90.
   PubMed Web of Science ®Google Scholar
• Li GY. 2017. Clinical observation on the treatment of lung adenocarcinoma of Ying-xu-du-yun type IIIb-IV EGFR mutant with nourishing yin and detoxifying prescription decoction combined with icotinib [master’s thesis]]. Hangzhou (ZJ): Zhejiang Chinese Medical University.
   Google Scholar
• Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C. 2011. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci. 56(2):275–284.
   PubMed Web of Science ®Google Scholar
• Li L, Wang S, Zheng F, Wu W, Hann SS. 2016. Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression. J Ethnopharmacol. 194:918–929.
   PubMed Web of Science ®Google Scholar
• Lin J, Wei L, Shen A, Cai Q, Xu W, Li H, Zhan Y, Hong Z, Peng J. 2013. Hedyotis diffusa Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer ctal cancer angiogenesis. Int J Oncol. 42(2):651–666.
   PubMed Web of Science ®Google Scholar
• Liu HS, Gao YH, Liu LH, Liu W, Shi QW, Dong M, Suzuki T, Kiyota H. 2016. Inhibitory effect of 13 taxane diterpenoids from Chinese yew (Taxus chinensis var. mairei) on the proliferation of HeLa cervical cancer cells. Biosci Biotechnol Biochem. 80(10):1883–1886.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. 2018. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 17(1):53.
   PubMedGoogle Scholar
• Liu X, Jiang T, Li X, Zhao C, Li J, Zhou F, Zhang L, Zhao S, Jia Y, Shi J, et al. 2020. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating the PI3K/AKT signalling pathway. J Cell Mol Med. 24(2):1529–1540.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen S, Cai J, Zhang E, Lan L, Zheng J, Liao L, Yang X, Zhou C, Du J. 2013. Traditional Chinese medicine syndrome-related herbal prescriptions in treatment of malignant tumors. J Tradit Chin Med. 33(1):19–26.
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun X, Liu H, Ma T, Shi J, Jia B, Zhao H, Wang F. 2014. Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. J Nucl Med. 55(5):818–823.
   PubMed Web of Science ®Google Scholar
• Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, et al. 2011. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 6(4):707–715.
   PubMed Web of Science ®Google Scholar
• Mao W, Yin H, Chen W, Zhao T, Wu S, Jin H, Du B, Tan Y, Zhang R, He Y. 2020. Network pharmacology and experimental evidence reveal dioscin suppresses proliferation, invasion, and EMT via Akt/GSK3b/mTOR signaling in lung adenocarcinoma. Drug Des Devel Ther. 14:2135–2147.
   PubMed Web of Science ®Google Scholar
• Marędziak M, Tomaszewski K, Polinceusz P, Lewandowski D, Marycz K. 2017. Static magnetic field enhances the viability and proliferation rate of adipose tissue-derived mesenchymal stem cells potentially through activation of the phosphoinositide 3-kinase/Akt (the PI3K/Akt) pathway. Electromagn Biol Med. 36(1):45–54.
   PubMed Web of Science ®Google Scholar
• Meng LZ, Lv GP, Hu DJ, Cheong KL, Xie J, Zhao J, Li SP. 2013. Effects of polysaccharides from different species of Dendrobium (Shihu) on macrophage function. Molecules. 18(5):5779–5791.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. 2010. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2):121–128.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Mo'men YS, Hussein RM, Kandeil MA. 2019. Involvement of the PI3K/Akt pathway in the protective effect of hesperidin against a chemically induced liver cancer in rats. J Biochem Mol Toxicol. 33(6):e22305.
   PubMed Web of Science ®Google Scholar
• Normanno N, Maiello MR, Chicchinelli N, Iannaccone A, Esposito C, De Cecio R, D'alessio A, De Luca A. 2017. Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opin Ther Targets. 21(2):159–165.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, et al. 2017. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2(1):e000168.
   PubMed Web of Science ®Google Scholar
• Rotow J, Bivona TG. 2017. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 17(11):637–658.
   PubMed Web of Science ®Google Scholar
• Saiprasad G, Chitra P, Manikandan R, Sudhandiran G. 2014. Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis. Eur J Cancer. 50(14):2489–2507.
   PubMed Web of Science ®Google Scholar
• Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, et al. 2018. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Cancer Sci. 109(10):3183–3196.
   PubMed Web of Science ®Google Scholar
• Song X, Wang Z, Liang H, Zhang W, Ye Y, Li H, Hu Y, Zhang Y, Weng H, Lu J, et al. 2017. Dioscin induces gallbladder cancer apoptosis by inhibiting ROS-mediated PI3K/Akt signalling. Int J Biol Sci. 13(6):782–793.
   PubMed Web of Science ®Google Scholar
• Tan AC. 2020. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 11(3):511–518.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. 2010. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17(1):77–88.
   PubMed Web of Science ®Google Scholar
• Virág L, Szabó C. 2002. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 54(3):375–429.
   PubMed Web of Science ®Google Scholar
• Wei W, Wu XM, Li YJ. 2010. Yao Li Shi Yan Fang Fa Xue [Methodology of Pharmacological Experiment]. 4th ed. Beijing: People's Medical Publishing House.
   Google Scholar
• Wong RS. 2011. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 30:87.
   PubMed Web of Science ®Google Scholar
• Wu H, Fan F, Liu Z, Shen C, Wang A, Lu Y. 2015. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Cancer Chemother Pharmacol. 76(2):307–315.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou Y. 2019. Shashen-Maidong decoction-mediated IFN-γ and IL-4 on the regulation of Th1/Th2 imbalance in RP rats. Biomed Res Int. 2019:1–7.
   Web of Science ®Google Scholar
• Yip PY. 2015. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res. 4(2):165–176.
   PubMed Web of Science ®Google Scholar
• Yu X, Sun S, Guo Y, Liu Y, Yang D, Li G, Lü S. 2018. Citri Reticulatae Pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine. J Ethnopharmacol. 220:265–282.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang Y, Liu X, Hou D, Gao T. 2015. Authentication of commercial processed Glehniae Radix (Beishashen) by DNA barcodes. Chin Med. 10:35.
   PubMed Web of Science ®Google Scholar